ArticleHeliyon2020
Temperature-dependent formulation of a hydrogel based on Hyaluronic acid-polydimethylsiloxane for biomedical applications.
Article in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 39 citations in OpenAlex.
- Injectable smart-blended hydrogel cross-linked with Vanillin to accelerate differentiation of intervertebral disc-derived stem cells (IVDSCs) for promoting degenerative nucleolus pulposus in a rat model.Inflammopharmacology · 2024Article
- The Utilisation of Hydrogels for iPSC-Cardiomyocyte Research.International journal of molecular sciences · 2023Review
- A fabricated hydrogel of hyaluronic acid/curcumin shows super-activity to heal the bacterial infected wound.AMB Express · 2023Article
- Hydrogel Formulations of Antibacterial Pyrazoles Using a Synthesized Polystyrene-Based Cationic Resin as a Gelling Agent.International journal of molecular sciences · 2023Article
- A Self-Forming Hydrogel from a Bactericidal Copolymer: Synthesis, Characterization, Biological Evaluations and Perspective Applications.International journal of molecular sciences · 2022Article
- Hyaluronidase Inhibitor-Incorporated Cross-Linked Hyaluronic Acid Hydrogels for Subcutaneous Injection.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyaluronic acid (HA), as a safe biomaterial with minimal immunogenicity, is being employed in a broad range of medical applications. Since unmodified HA has a high potential for biodegradation in the physiological condition, herein, an HA-based cross-linked hydrogel was formulated using polydimethylsiloxane-diglycidyl ether terminated (PDMS-DG) via epoxide-OH reaction. The formation of HA-PDMS hydrogel was confirmed using FTIR, NMR, and FESEM. Temperature demonstrated a critical role in the physicochemical properties of the final products. Gel-37, which formed at 37 °C, had a higher modification degree (MD) and more stability against hyaluronidase and oxidative stress than the hydrogel formulated at 25 °C (Gel-25). In addition, the swelling ratio, roughness, and porous network topology of Gel-25 and Gel-37 were different. The rheology measurement indicated that HA-PDMS hydrogel had a stable viscoelastic character. The hydrogel was also biocompatible, non-cytotoxic, and considerably stable during 7-months storage. Overall, various determined parameters confirmed that HA-PDMS hydrogel is worth using in different medical applications. Keywords: Hyaluronic acid; Polydimethylsiloxane-diglycidyl ether terminated; Hydrogels; Long-term stability; Viscoelastic behavior; Biocompatibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.